Title:
The Expression Project for Oncology (expO) View
Indication:
Other
Location:
Texas Oncology-Canton
Title:
Phase III Randomized Study of Standard versus Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients with Stage II-III Non-Small Cell Lung Cancer and Poor Performance Status View
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Title:
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements View
Indication:
Solid Tumors
Location:
Texas Oncology-Canton
Title:
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma View
Indication:
Lymphomas
Location:
Texas Oncology-Canton
Title:
An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma View
Indication:
Hematologic
Location:
Texas Oncology-Canton
Title:
A Phase 3 randomized, open-label, multicenter study assessing the clinical benefit of isatuximab (SAR650984) in combination with bortezomib (Velcade), lenalidomide (Revlimid) and dexamethasone versus bortezomib, lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not eligible for transplant View
Indication:
Hematologic
Location:
Texas Oncology-Canton
Title:
PI/II Cholangiocarcinoma CX-4945 w Gem View
Description: A Phase I/II Study of CX-4945 in Combination with Gemcitabine plus Cisplatin in the Frontline Treatment of Patients with Cholangiocarcinoma (S4-13-001)
Indication:
Biliary Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
Nivo in Advanced/Met Malignancies View
Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)
Indication:
Biliary Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
STAR INCB054828 Urothelial FGF/FGFR View
Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations
Indication:
Bladder Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
STAR INCB054828 Urothelial FGF/FGFR View
Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations
Indication:
Bladder Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
STAR Ph2 enfortumab (ASG-22CE)Urothelial View
Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001
Indication:
Bladder Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
Sitravatinib + Nivo Adv/Met Urothelial View
Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)
Indication:
Bladder Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Brain Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Adj Therapy Node+orHRNode-3-Inv TNBC View
Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)
Indication:
Breast Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Breast Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Sacituzumab Govitecan(SASSY) vs PC mTNBC View
Description: An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments (IMMU-132-05)
Indication:
Breast Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View
Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors
Indication:
Breast Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Non-Interv study Palbo HR+/HER2 AdvBC View
Description: POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)
Indication:
Breast Cancer
Location:
Texas Oncology-Canton
Title:
Ph3 SYD985 HER2+ unresect adv/mBC View
Description: SYD985.002: A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician''s choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer
Indication:
Breast Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Destiny1:Ph2 DS-8201a HER2+ unresect/mBC View
Description: DS8201-A-U201: A PHASE 2, MULTICENTER, OPEN-LABEL STUDY OF DS-8201a, AN ANTI-HER2-ANTIBODY DRUG CONJUGATE (ADC) FOR HER2-POSITIVE, UNRESECTABLE AND/OR METASTATIC BREAST CANCER SUBJECTS PREVIOUSLY TREATED WITH T-DM1
Indication:
Breast Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph3 Abemaciclib HR+ HER2- (monarchE) View
Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Indication:
Breast Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Phase 1/2a BMS-986253 + Nivo View
Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)
Indication:
Breast Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Cervical Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Nivo in Advanced/Met Malignancies View
Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)
Indication:
Cervical Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View
Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors
Indication:
Cervical Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Colon Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph3 BBI-608/FOLFIRI +/- Bev, 2L mCRC View
Description: CanStem303C: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC)
Indication:
Colon Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph1 TSR-022 Adv Solid Tumors View
Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)
Indication:
Colon Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph 2/3 Nivo 1L mCRC View
Description: An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer (CA209-9X8)
Indication:
Colon Cancer
Location:
Texas Oncology-Canton
Phase: II/III
Title:
Phase 1/2a BMS-986253 + Nivo View
Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)
Indication:
Colon Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
PhI/II PK Multi Tumor SubQ Nivo Mono View
Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)
Indication:
Colon Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
PhIb/2 Lenvatinib (E7080)+Pembro Solids View
Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Nivo in Advanced/Met Malignancies View
Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Esophageal Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View
Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Nivo in Advanced/Met Malignancies View
Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)
Indication:
Gastric Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View
Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors
Indication:
Gastric Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
PhIb/2 Lenvatinib (E7080)+Pembro Solids View
Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Nivo in Advanced/Met Malignancies View
Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
Molecular Markers - Malignant Tumors View
Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)
Indication:
Hematologic
Location:
Texas Oncology-Canton
Phase: IV
Title:
Ph3 HR MDS, CMML, AML View
Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia
Indication:
Hematologic
Location:
Texas Oncology-Canton
Phase: III
Title:
informCLL™ Registry View
Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)
Indication:
Leukemia
Location:
Texas Oncology-Canton
Phase: IV
Title:
Ph 1/2 PIM kinase Adv Malignancies View
Description: A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101)
Indication:
Leukemia
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph3b 1L CLL debulk combo View
Description: A phase 3b study in previously untreated Chronic Lymphocytic Leukemia (CLL) subjects, excluding those with the 17p deletion, to evaluate debulking regimens prior to initiating venetoclax combination therapy (M16-788)
Indication:
Leukemia
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph3 HR MDS, CMML, AML View
Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia
Indication:
Leukemia
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Liver Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Phase 1/2a BMS-986253 + Nivo View
Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)
Indication:
Liver Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
PhI/II PK Multi Tumor SubQ Nivo Mono View
Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)
Indication:
Liver Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
PhIb/2 Lenvatinib (E7080)+Pembro Solids View
Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Ph2 Combo Therapies IO NSCLC-FRACTION View
Description: CA018-001/CA018-001A: Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced Non-small Cell Lung Cancer (FRACTION-Lung)
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View
Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph3b/4 Safety Nivo+Ipi 1L, 2L NSCLC View
Description: CA209-817: A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: III/IV
Title:
Ph 3 pembro+ipi, 1L adv/rec NSCLC View
Description: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors are PD-L1 Positive (TPS > or = to 50%) (KEYNOTE-598)- MK-3475-598
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph1/1b MGCD516 Solid tumors View
Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph2 MGCDs+Nivo NSCLC View
Description: A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (MRTX-500)
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph1 TSR-022 Adv Solid Tumors View
Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Atezo Rollover for GNE & Roche View
Description: BO39633 (IMbrella A), An open-Label, Multicenter Extension and Long-Term Observational Study in Patients Previously Enrolled in A Genentech- and/or F.Hoffman-La Roche Ltd. sponsored Atezolizumab Study
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: IV
Title:
Ph2 pembro Adv NSCLC View
Description: A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab (MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)(MK3475-495)
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
STAR Ph2 Poziotinib EGFR/HER2 NSCLC View
Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph3 Adj canakinumab NSCLC View
Description: A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Cypress 1: Ph 2 AM0010+Pembro NSCLC View
Description: An Open-Label Randomized Phase 2 Trial of AM0010 in Combination with Pembrolizumab vs. Pembrolizumab Alone as First-line Therapy in Patients with Stage IV/Metastatic Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (≥ 50%) (AM0010-201)
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
Cypress 2: Ph2 AM0010+Nivo NSCLC View
Description: An Open-label Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1 (AM0010-202)
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
Phase 1/2a BMS-986253 + Nivo View
Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
STAR Ph2 Brigatinib ALK+ NSCLC View
Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
PhI/II PK Multi Tumor SubQ Nivo Mono View
Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
STAR Brentux in older pts w/HL 1L View
Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above
Indication:
Lymphomas
Location:
Texas Oncology-Canton
Phase: II
Title:
TGR-1202 +/- Ublituximab in NHL View
Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin''s Lymphoma (UTX-TGR-205)
Indication:
Lymphomas
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph3 Rituximab +/- Ibrutinib tx-naive FL View
Description: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton''s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma - PCYC-1141-CA
Indication:
Lymphomas
Location:
Texas Oncology-Canton
Phase: III
Title:
STAR Ph1/2 Tazemetostat r/r DLBCL & FL View
Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101
Indication:
Lymphomas
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Ph3 Polatuzumab 1L DLBCL [POLARIX] View
Description: (GO39942): A PHASE III, MULTICENTER, RANDOMIZED,DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB AND CHP (R-CHP) VERSUS RITUXIMAB AND CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
Indication:
Lymphomas
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph2 R/R MCL (CITADEL-205) View
Description: A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kä Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)- INCB050465-205
Indication:
Lymphomas
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph1b/2 R/R FL, R/R DLBCL View
Description: A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA AND RITUXIMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (GO29834)
Indication:
Lymphomas
Location:
Texas Oncology-Canton
Phase: I/II
Title:
PhIb/2 Lenvatinib (E7080)+Pembro Solids View
Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)
Indication:
Melanoma
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Melanoma
Location:
Texas Oncology-Canton
Phase: I
Title:
STAR Ph2 Pembro Recurr/Meta Cut. SCC View
Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)
Indication:
Melanoma
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph1 TSR-022 Adv Solid Tumors View
Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)
Indication:
Melanoma
Location:
Texas Oncology-Canton
Phase: I
Title:
PhI/II PK Multi Tumor SubQ Nivo Mono View
Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)
Indication:
Melanoma
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Nivo in Advanced/Met Malignancies View
Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)
Indication:
Mesothelioma
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph 1/2 PIM kinase Adv Malignancies View
Description: A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101)
Indication:
Myelodysplastic Syndrome
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph3 HR MDS, CMML, AML View
Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia
Indication:
Myelodysplastic Syndrome
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph 1/2 PIM kinase Adv Malignancies View
Description: A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101)
Indication:
Myelofibrosis
Location:
Texas Oncology-Canton
Phase: I
Title:
STAR Ph2 Itacitinib +/- Ruxo in MF View
Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Indication:
Myelofibrosis
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph 1/2 PIM kinase Adv Malignancies View
Description: A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101)
Indication:
Myelomas
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph4 Ixazomib+Lena & Dex MM (MM-6) View
Description: C16038: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen
Indication:
Myelomas
Location:
Texas Oncology-Canton
Phase: IV
Title:
Ph3 Dara high-risk SMM View
Description: A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma (54767414SMM3001)
Indication:
Myelomas
Location:
Texas Oncology-Canton
Phase: III
Title:
Nivo in Advanced/Met Malignancies View
Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)
Indication:
Neuroendocrine Tumors
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Ovarian Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View
Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors
Indication:
Ovarian Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View
Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523
Indication:
Ovarian Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
FOLFOX +/1 AM0010 Panc View
Description: A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen (AM0010-301)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Phase 1/2a BMS-986253 + Nivo View
Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Nivo in Advanced/Met Malignancies View
Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)
Indication:
Penile Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View
Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View
Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View
Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors
Indication:
Prostate Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
STAR Ph2 Rucaparib mCRPC (TRITON 2) View
Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052
Indication:
Prostate Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
STAR Rucaparib v PhysC mCRPC (TRITON3) View
Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)
Indication:
Prostate Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph1/1b MGCD516 Solid tumors View
Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)
Indication:
Prostate Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Rectal Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Nivo in Advanced/Met Malignancies View
Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)
Indication:
Rectal Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph3 BBI-608/FOLFIRI +/- Bev, 2L mCRC View
Description: CanStem303C: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC)
Indication:
Rectal Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph 2/3 Nivo 1L mCRC View
Description: An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer (CA209-9X8)
Indication:
Rectal Cancer
Location:
Texas Oncology-Canton
Phase: II/III
Title:
PhIb/2 Lenvatinib (E7080)+Pembro Solids View
Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)
Indication:
Renal Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Lenvat+ever/pemb vs sunit 1L RCC [CLEAR] View
Description: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma(E7080-G000-307)(CLEAR)
Indication:
Renal Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph3 Pembro RCC post nephrectomy View
Description: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)
Indication:
Renal Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph1/1b MGCD516 Solid tumors View
Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)
Indication:
Renal Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Phase 1/2a BMS-986253 + Nivo View
Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)
Indication:
Renal Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
PhI/II PK Multi Tumor SubQ Nivo Mono View
Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)
Indication:
Renal Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
STAR Ph2 Pembro Recurr/Meta Cut. SCC View
Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)
Indication:
Skin Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
Phase 1/2a BMS-986253 + Nivo View
Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)
Indication:
Skin Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Solid Tumors
Location:
Texas Oncology-Canton
Phase: I
Title:
Nivo in Advanced/Met Malignancies View
Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)
Indication:
Solid Tumors
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View
Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors
Indication:
Solid Tumors
Location:
Texas Oncology-Canton
Phase: I
Title:
Molecular Markers - Malignant Tumors View
Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)
Indication:
Solid Tumors
Location:
Texas Oncology-Canton
Phase: IV
Title:
Ph1/1b MGCD516 Solid tumors View
Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)
Indication:
Solid Tumors
Location:
Texas Oncology-Canton
Phase: I
Title:
Phase 1/2a BMS-986253 + Nivo View
Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)
Indication:
Solid Tumors
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Nivo in Advanced/Met Malignancies View
Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)
Indication:
Testicular Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
Nivo in Advanced/Met Malignancies View
Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)
Indication:
Thymomas
Location:
Texas Oncology-Canton
Phase: II
Title:
Nivo in Advanced/Met Malignancies View
Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)
Indication:
Thyroid Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
PhIb/2 Lenvatinib (E7080)+Pembro Solids View
Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
STAR INCB054828 Urothelial FGF/FGFR View
Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations
Indication:
Urothelial Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
STAR INCB054828 Urothelial FGF/FGFR View
Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations
Indication:
Urothelial Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View
Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors
Indication:
Urothelial Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
STAR Ph2 enfortumab (ASG-22CE)Urothelial View
Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001
Indication:
Urothelial Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
Sitravatinib + Nivo Adv/Met Urothelial View
Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
Nivo in Advanced/Met Malignancies View
Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)
Indication:
Uterine Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
Nivo in Advanced/Met Malignancies View
Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)
Indication:
Vaginal Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View
Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors
Indication:
Vaginal Cancer
Location:
Texas Oncology-Canton
Phase: I